Management of patients with homozygous familial hypercholesterolemia

American Journal of Managed Care

Volumn 19, Issue 13 SUPPL., 2013, Pages

  Ziajka, Paul E ^a  

^a Florida Lipid Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; ORPHAN DRUG; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; LOW DENSITY LIPOPROTEIN; OLIGONUCLEOTIDE;

ALLELE; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SCREENING; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; MANAGED CARE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; BLOOD; DRUG APPROVAL; FEMALE; HYPERLIPOPROTEINEMIA TYPE II; LOW FAT DIET; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; PLASMAPHERESIS; PROCEDURES; PROGNOSIS; RARE DISEASE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BENZIMIDAZOLES; COMBINED MODALITY THERAPY; DIET, FAT-RESTRICTED; DRUG APPROVAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; OLIGONUCLEOTIDES; PLASMAPHERESIS; PROGNOSIS; RARE DISEASES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84904959600     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223(2):262-268.
2. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S1-S8.
3. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S9-S17.
4. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society [published online September 12, 2013]. Eur Heart J.
5. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13(4):285-296.
6. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013;24(4):288-294.
7. Talmud PJ, Shah S, Wittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013;381:1293-1301.
8. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008;28(4):777-785. (Pubitemid 351651345)
9. FDA briefing document NDA 203858: lomitapide mesylate capsules 5 mg, 10 mg, 20 mg. FDA website. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM323841.pdf. Published October 17, 2012. Accessed October 13, 2013.
10. Kynamro prescribing information. Cambridge, MA: Genzyme Corp; 2013.
11. Stein EA, Honarpour N, Wasserman SM, et al. PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia [published online 2013]. Circulation.
12. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis. 2010;208(2): 317-321.
13. Juxtapid prescribing information. Cambridge, MA: Aegerion Pharmaceuticals; 2012.
14. Lee WP, Datta BN, Ong BB, Rees A, Halcox J. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia. Am J Cardiovasc Drugs. 2011;11(6): 363-370.
15. Daniels SR, Gidding SS, de Ferranti SD; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 suppl):S30-S37.
16. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-239. (Pubitemid 38924592)
17. Ito MK, McGowan MP, Moriarty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5(3 suppl):S38-S45.
18. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998-1006.
19. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14(1):67-70.
20. FDA approves new orphan drug for rare cholesterol disorder [press release]. FDA website. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm333285.htm. Published December 26, 2012. Accessed August 8, 2013.
21. FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder [press release]. FDA website. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm337195.htm. Published January 29, 2013. Accessed August 8, 2013.
22. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single- arm, open-label, phase 3 study. Lancet. 2013;381(9860):40-46.
23. National Institutes of Health. ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT00943306?term=lomitapide&rank=1. Accessed November 7, 2013.
24. FDA briefing document, NDA 203568: mipomersen sodium injection 200 mg/mL. FDA website. http://www.fda.gov/downloads/advisorycommittees/ committeesmeetingmaterials/drugs/ endocrinologicandmetabolicdrugsadvisorycommittee/ucm323927.pdf. Published October 18, 2012. Accessed October 12, 2013.
25. National Institutes of Health. ClinicalTrials.gov website. http://clinicaltrials.gov/ct2/show/NCT00694109?term=mipomersen&rank=15. Accessed November 7, 2013.
26. Smith RJ, Hiatt WR. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder. JAMA Intern Med. 2013;173(16):1491-1492.
27. Physicians' Desk Reference Inc. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters; 2013.